Clinical trial NCT02852187: Single Center Study Comparing MOBIS II ST vs MOBIS PEEK
Official title: Prospective, Randomized, Data Registry Study of MOBIS II Structural Titanium (ST) Interbody Cage Compared to MOBIS Peek Cage for the Treatment of Spondylolisthesis and Degenerative Disc Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Lumbar Disc Disease
Keywords: Intervertebral Disc Degeneration
Lumbar Spinal Disease
Lead sponsor: Signus Medizintechnik GmbH
Sponsor class: INDUSTRY
First posted: 2016-08-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective randomized clinical study comparing SIGNUS MOBIS PEEK vs SIGNUS MOBIS II ST in patients with Degenerative Disc Disease at one or two contiguous levels from L2-S1

Detailed description: The protocol includes skeletally mature patients both male and female, 18 to 89 years old, with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. Patients may also have up to a Grade I spondylolisthesis or retrolisthesis at the involved level(s). Patient should have completed at least six (6) months of non-operative treatment. Patients may have had a previous non-fusion surgery at the involved spinal level(s) and will be followed clinically up to two years.

Eligibility criteria: Inclusion Criteria:

1. The patient has symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1.
2. The patient has documented conservative (non-operative) treatment for at least 6 months.
3. The patient has a VAS back pain of ≥ 60 mm.
4. The patient has an ODI ≥ 40%.
5. The patient is at least 18 years of age and skeletally mature.
6. The general condition of the patient is appropriate for surgery, as evaluated by the Investigator.
7. The patient is willing and able to comply with study requirements.
8. The patient has agreed to participate in the study.

Exclusion Criteria:

1. The patient has undergone any prior spinal fusion surgery at the proposed treatment level(s).
2. The patient has osteoporosis or severe osteopenia as determined by the Investigator. A clinical SCORE calculator may be utilized for females over 40 years of age.
3. The patient has grade 2 or higher spondylolisthesis or retrolisthesis at the affected level(s).
4. The patient has diffuse multilevel neoplastic disease such that no adjacent normal segments exist for engagement or instrumentation.
5. The patient has an active infection.
6. The patient is pregnant or is planning on becoming pregnant in the next two years.
7. The patient is mentally ill or has a history of drug abuse or severe depression/ psychosocial issues.
8. The patient has a known allergy to polyether ether ketone (PEEK), stainless steel or tantalum/titanium.
9. The patient is currently enrolled in an investigational spine study.
10. The patient has rheumatoid arthritis, ankylosing spondylitis or other autoimmune disease.
11. The patient has symptomatic fibrous arachnoiditis

Primary outcomes:
measure: Fusion rates
timeFrame: 24 Months
Secondary outcomes:
measure: Subsidence
timeFrame: 24 Months
measure: Patient Reported Outcomes: Visual Analog Scale (VAS)
timeFrame: Through 24 Months
measure: Patient Reported Outcomes: Oswestry Disability Index
timeFrame: Through 24 Months
measure: Patient Reported Outcomes: Evaluations of Quality of Life (QOL) by the EQ-5D-5L
timeFrame: Through 24 Months
Other outcomes:
Locations:
city: East Syracuse
country: United States
facility: Upstate Orthopedics
state: New York
Study officials:
affiliation: Upstate Orthopedics
name: William F. Lavelle, MD
role: PRINCIPAL_INVESTIGATOR
References: